1-5 of 5
Steven D. Green
Close
Sort by
Journal Articles

Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia

Hassan Awada, Mina Abdelmalek, Tara L. Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark G. Faber, Arya Roy, Ashish Gupta, Matthew Gravina, Sheeba Ba Aqeel, Alankrita Taneja, Pamela J. Sung, Steven D. Green, Amanda Przespolewski, James E. Thompson, Elizabeth A. Griffiths, Eunice S. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 135–136.
https://doi.org/10.1182/blood-2022-168482
Published: 2022
Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal
Journal: Blood
Blood (2022) 140 (Supplement 1): 594–595.
https://doi.org/10.1182/blood-2022-159086
Published: 2022
Journal Articles

Phase II Study of Tagraxofusp in Newly Diagnosed Secondary Acute Myeloid Leukemia (S-AML) after Previous Exposure to Hypomethylating Agents (TAGALONG Study)

Steven D. Green, Brian Parkin, Catherine Lai, Ivana Gojo, Matthew C. Foster, Joshua F. Zeidner
Journal: Blood
Blood (2022) 140 (Supplement 1): 11749–11750.
https://doi.org/10.1182/blood-2022-170738
Published: 2022
Journal Articles

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Mark G. Faber, Jeffrey Baron, Han Yu, Hassan Awada, Tara L. Cronin, James E. Thompson, Amanda Przespolewski, Steven D. Green, Pamela J. Sung, Elizabeth A. Griffiths, Eunice S. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9010–9012.
https://doi.org/10.1182/blood-2022-164707
Published: 2022
Journal Articles

Retrospective Outcomes of Prolonged-Duration Calcineurin Inhibitor Immunosuppression in Severe Aplastic Anemia

Steven D. Green, MD, Joyatee M. Sarker, PhD, Erica B. Bernhardt, MD, Muhammad Khawaja, MBBS,MPH, Robert P. Nelson, Jr., MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1186.
https://doi.org/10.1182/blood.V130.Suppl_1.1186.1186
Published: 2017